Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ENLV
ENLV logo

ENLV Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Enlivex Ltd (ENLV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.610
1 Day change
-1.93%
52 Week Range
2.100
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Enlivex Ltd (ENLV) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, there are no significant positive catalysts or trading signals, and the stock lacks recent financial performance data. While the analyst rating is positive with a raised price target, the lack of immediate positive momentum and unclear financials suggest holding off on investment for now.

Technical Analysis

The technical indicators for ENLV are bearish. The MACD histogram is negative and contracting, RSI is in the neutral zone at 26.82, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support levels are at 0.622 and 0.58, with resistance at 0.69 and 0.759.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
4

Positive Catalysts

  • Analyst Raghuram Selvaraju from H.C. Wainwright raised the price target to $20 from $13, citing completed debt financing and resources for Allocetra clinical development.

Neutral/Negative Catalysts

  • No significant hedge fund or insider trading activity. No recent news or congress trading data. Technical indicators are bearish, and there is no recent financial performance data available.

Financial Performance

No financial performance data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst Raghuram Selvaraju maintains a Buy rating with an increased price target of $20, up from $13.

Wall Street analysts forecast ENLV stock price to rise
2 Analyst Rating
Wall Street analysts forecast ENLV stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.581
sliders
Low
13
Averages
13
High
13
Current: 0.581
sliders
Low
13
Averages
13
High
13
H.C. Wainwright
Raghuram Selvaraju
Buy
maintain
$13 -> $20
AI Analysis
2026-04-07
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$13 -> $20
AI Analysis
2026-04-07
maintain
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Enlivex Therapeutics to $20 from $13 and keeps a Buy rating on the shares. The company's debt financing is complete and provides resources to conduct Allocetra clinical development, the analyst tells investors in a research note.
D. Boral Capital
D. Boral Capital
Buy -> Hold
downgrade
2025-11-24
Reason
D. Boral Capital
D. Boral Capital
Price Target
2025-11-24
downgrade
Buy -> Hold
Reason
D. Boral Capital downgraded Enlivex Therapeutics to Hold from Buy with no price target after the company announced a $212M private placement for 212M shares priced at $1.00 to initiate a digital asset treasury strategy centered on the accumulation of RAIN tokens designed for on-chain predictive markets, options trading, and transparent data aggregation. The firm, which notes its valuation models had been based on the value of the therapeutic, says those are "less relevant now" and it needs some time to understand how to value the company following the shift.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ENLV
Unlock Now

People Also Watch